Genotype-Based Ancestral Background Consistently Predicts Efficacy and Side Effects across Treatments in CATIE and STAR*D

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Adkins, Daniel E ^a   Souza, Renan P ^a   Åberg, Karolina ^a   Clark, Shaunna L ^a   McClay, Joseph L ^a   Sullivan, Patrick F ^b,c   van den Oord, Edwin J C G ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; BUSPIRONE; CITALOPRAM; CLOZAPINE; MIRTAZAPINE; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SERTRALINE; VENLAFAXINE; ZIPRASIDONE; GENETIC MARKER; PRESCRIPTION DRUG;

ADULT; ADVERSE OUTCOME; ALGORITHM; APPETITE; ARTICLE; BODY WEIGHT; CLINICAL EFFECTIVENESS; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ETHNICITY; GENETIC MARKER; GENETIC TRAIT; GENOTYPING TECHNIQUE; HEART RATE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MULTICENTER STUDY (TOPIC); PHENOTYPE; PREDICTION; QT PROLONGATION; RACE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SELF REPORT; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; GENETIC ASSOCIATION; GENETIC SCREENING; GENETICS; GENOTYPE; HUMAN GENOME; PERSONALIZED MEDICINE; PROCEDURES; TREATMENT OUTCOME;

GENETIC MARKERS; GENETIC TESTING; GENOME, HUMAN; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; POLYMORPHISM, SINGLE NUCLEOTIDE; PRESCRIPTION DRUGS; SELF REPORT; TREATMENT OUTCOME;

EID: 84873538780     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055239     Document Type: Article

References (44)

1. Ashley EA, Butte AJ, Wheeler MT, Chen R, Klein TE, et al. (2010) Clinical assessment incorporating a personal genome. Lancet 375: 1525-1535.
2. Simon GE, Von Korff M, Rutter CM, Peterson DA, (2001) Treatment process and outcomes for managed care patients receiving new antidepressant prescriptions from psychiatrists and primary care physicians. Arch Gen Psychiatry 58: 395-401.
3. Couzin J, (2008) Science and commerce. Gene tests for psychiatric risk polarize researchers. Science 319: 274-277.
4. Braff DL, Freedman R, (2008) Clinically responsible genetic testing in neuropsychiatric patients: a bridge too far and too soon. Am J Psychiatry 165: 952-955.
5. Crowley JJ, Sullivan PF, McLeod HL, (2009) Pharmacogenomic genome-wide association studies: lessons learned thus far. Pharmacogenomics 10: 161-163.
6. Holden C, (2003) Race and medicine. Science 302: 594-596.
7. Wilson JF, Weale ME, Smith AC, Gratrix F, Fletcher B, et al. (2001) Population genetic structure of variable drug response. Nat Genet 29: 265-269.
8. Clark SL, Adkins DE, van den Oord E, (2011) Analysis of efficacy and side effects in CATIE demonstrates drug response subgroups and potential for personalized medicine. Schizophrenia Research 132: 114-120.
9. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, et al. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223.
10. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, et al. (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163: 28-40.
11. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, et al. (2003) The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 29: 15-31.
12. Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, et al. (2004) Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 25: 119-142.
13. Sullivan PF, Lin D, Tzeng JY, van den Oord E, Perkins D, et al. (2008) Genomewide association for schizophrenia in the CATIE study: results of stage 1. Mol Psychiatry 13: 570-584.
14. Garriock HA, Kraft JB, Shyn SI, Peters EJ, Yokoyama JS, et al. (2010) A Genomewide Association Study of Citalopram Response in Major Depressive Disorder. Biological Psychiatry 67: 133-138.
15. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559-575.
16. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, et al. (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38: 904-909.
17. McClay JL, Adkins DE, Aberg K, Bukszar J, Khachane AN, et al. (2011) Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology 36: 616-626.
18. Aberg K, Adkins DE, Liu Y, McClay JL, Bukszar J, et al. (2010) Genome-wide association study of antipsychotic-induced QTc interval prolongation. Pharmacogenomics J.
19. Adkins DE, Aberg K, McClay JL, Hettema JM, Kornstein SG, et al. (2010) A genomewide association study of citalopram response in major depressive disorder-a psychometric approach. Biol Psychiatry 68: e25-27.
20. Adkins DE, Aberg K, McClay JL, Bukszar J, Zhao Z, et al. (2011) Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Mol Psychiatry 16: 321-332.
21. Aberg K, Adkins DE, Bukszar J, Webb BT, Caroff SN, et al. (2010) Genomewide association study of movement-related adverse antipsychotic effects. Biol Psychiatry 67: 279-282.
22. McClay JL, Adkins DE, Aberg K, Stroup S, Perkins DO, et al. (2011) Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol Psychiatry 16: 76-85.
23. Adkins DE, Clark SL, Aberg K, Hettema JM, Bukszar J, et al. (2012) Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D. Translational Psychiatry 2: e129.
24. Adkins DE, Khachane AN, McClay JL, Aberg K, Bukszar J, et al. (2012) SNP-based analysis of neuroactive ligand-receptor interaction pathways implicates PGE2 as a novel mediator of antipsychotic treatment response: Data from the CATIE study. Schizophrenia Research 135: 200-201.
25. Garriock HA, Kraft JB, Shyn SI, Peters EJ, Yokoyama JS, et al. (2010) A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry 67: 133-138.
26. Anderson CA, Pettersson FH, Clarke GM, Cardon LR, Morris AP, et al. (2010) Data quality control in genetic case-control association studies. Nat Protoc 5: 1564-1573.
27. van den Oord EJ, Adkins DE, McClay J, Lieberman J, Sullivan PF, (2009) A systematic method for estimating individual responses to treatment with antipsychotics in CATIE. Schizophr Res 107: 13-21.
28. Robinson GK, (1991) That BLUP is a Good Thing: The Estimation of Random Effects. Statistical Science 6: 15-32.
29. Clark SL, Adkins DE, Aberg K, Hettema JM, McClay JL, et al. (2012) Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D. Psychological Medicine 42: 1151-1162.
30. Benjamini Y, Hochberg Y, (1995) Controlling the False Discovery Rate- a Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B-Methodological 57: 289-300.
31. Storey J, (2003) The positive false discovery rate: A Bayesian interpretation and the q-value. Ann Stat 31: 2013-2035.
32. de Bakker PIW, Ferreira MAR, Jia XM, Neale BM, Raychaudhuri S, et al. (2008) Practical aspects of imputation-driven meta-analysis of genome-wide association studies. Human Molecular Genetics 17: R122-R128.
33. Price AL, Butler J, Patterson N, Capelli C, Pascali VL, et al. (2008) Discerning the ancestry of European Americans in genetic association studies. PLoS Genet 4: e236.
34. Cohen J, (1983) The Cost of Dichotomization. Applied Psychological Measurement 7: 249-253.
35. MacCallum RC, Zhang SB, Preacher KJ, Rucker DD, (2002) On the practice of dichotomization of quantitative variables. Psychological Methods 7: 19-40.
36. Mountain JL, Risch N, (2004) Assessing genetic contributions to phenotypic differences among 'racial' and 'ethnic' groups. Nature Genetics 36: S48-S53.
37. Karter AJ, (2003) Commentary: Race, genetics, and disease- in search of a middle ground. International Journal of Epidemiology 32: 26-28.
38. Williams DR, Sternthal M, (2010) Understanding Racial-ethnic Disparities in Health: Sociological Contributions. Journal of Health and Social Behavior 51: S15-S27.
39. Olfson M, Marcus SC, (2009) National patterns in antidepressant medication treatment. Arch Gen Psychiatry 66: 848-856.
40. Zou H, Hastie T, Tibshirani R, (2006) Sparse principal component analysis. Journal of Computational and Graphical Statistics 15: 265-286.
41. Paul D, Bair E, Hastie T, Tibshirani R, (2008) "Preconditioning" for feature selection and regression in high-dimensional problems'. Annals of Statistics 36: 1595-1618.
42. Tian C, Gregersen PK, Seldin MF, (2008) Accounting for ancestry: population substructure and genome-wide association studies. Hum Mol Genet 17: R143-150.
43. Tian C, Hinds DA, Shigeta R, Kittles R, Ballinger DG, et al. (2006) A genomewide single-nucleotide-polymorphism panel with high ancestry information for African American admixture mapping. Am J Hum Genet 79: 640-649.
44. Tian C, Hinds DA, Shigeta R, Adler SG, Lee A, et al. (2007) A genomewide single-nucleotide-polymorphism panel for Mexican American admixture mapping. Am J Hum Genet 80: 1014-1023.